JP2003524582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524582A5 JP2003524582A5 JP2000538689A JP2000538689A JP2003524582A5 JP 2003524582 A5 JP2003524582 A5 JP 2003524582A5 JP 2000538689 A JP2000538689 A JP 2000538689A JP 2000538689 A JP2000538689 A JP 2000538689A JP 2003524582 A5 JP2003524582 A5 JP 2003524582A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- kit
- fluvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 21
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 21
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 21
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 16
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 13
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 13
- 229960003765 fluvastatin Drugs 0.000 description 13
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 11
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 11
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 11
- 229960004844 lovastatin Drugs 0.000 description 11
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 11
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 11
- 229950009116 mevastatin Drugs 0.000 description 11
- 229960002965 pravastatin Drugs 0.000 description 11
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 11
- 229960002855 simvastatin Drugs 0.000 description 11
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 10
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 10
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 10
- 229960005110 cerivastatin Drugs 0.000 description 10
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 10
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 10
- 229950003040 dalvastatin Drugs 0.000 description 10
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- -1 flindostatin Chemical compound 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 6
- 229960005370 atorvastatin Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229960001445 alitretinoin Drugs 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 2
- 229960001770 atorvastatin calcium Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 125000002678 retinoid group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6943297P | 1997-12-12 | 1997-12-12 | |
| US60/069,432 | 1997-12-12 | ||
| PCT/US1998/023480 WO1999030706A1 (en) | 1997-12-12 | 1998-11-04 | ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003524582A JP2003524582A (ja) | 2003-08-19 |
| JP2003524582A5 true JP2003524582A5 (https=) | 2006-01-05 |
Family
ID=22088939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000538689A Pending JP2003524582A (ja) | 1997-12-12 | 1998-11-04 | 抗高脂血症性スタチン−Ｌｐ（ａ）阻害剤配合物 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1037623A1 (https=) |
| JP (1) | JP2003524582A (https=) |
| KR (1) | KR20010033017A (https=) |
| AU (2) | AU1306099A (https=) |
| BR (1) | BR9813539A (https=) |
| CA (1) | CA2299397A1 (https=) |
| HU (1) | HUP0100349A3 (https=) |
| IL (1) | IL134364A0 (https=) |
| IS (1) | IS5385A (https=) |
| NO (1) | NO20002965L (https=) |
| NZ (1) | NZ502874A (https=) |
| PL (1) | PL343851A1 (https=) |
| WO (1) | WO1999030706A1 (https=) |
| ZA (1) | ZA9811349B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0996459B1 (en) | 1997-01-07 | 2005-09-21 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| EP1076091A1 (en) * | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| CA2396157A1 (en) * | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
| WO2001058443A1 (fr) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | INHIBITEURS DE TNF-$g(a) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| AU3473193A (en) * | 1992-01-17 | 1993-08-03 | Procter & Gamble Company, The | Treatment for atherosclerosis |
| CA2129732A1 (en) * | 1992-02-25 | 1993-09-02 | Alain Martin | Cytoprotective compositions containing pyruvate and antioxidants |
| US5720963A (en) * | 1994-08-26 | 1998-02-24 | Mary Kay Inc. | Barrier disruption treatments for structurally deteriorated skin |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| EP0738510A3 (fr) * | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
| AU732465B2 (en) * | 1996-04-17 | 2001-04-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
-
1998
- 1998-11-04 EP EP98956562A patent/EP1037623A1/en not_active Ceased
- 1998-11-04 JP JP2000538689A patent/JP2003524582A/ja active Pending
- 1998-11-04 IL IL13436498A patent/IL134364A0/xx unknown
- 1998-11-04 CA CA002299397A patent/CA2299397A1/en not_active Abandoned
- 1998-11-04 WO PCT/US1998/023480 patent/WO1999030706A1/en not_active Ceased
- 1998-11-04 HU HU0100349A patent/HUP0100349A3/hu unknown
- 1998-11-04 PL PL98343851A patent/PL343851A1/xx unknown
- 1998-11-04 KR KR1020007006370A patent/KR20010033017A/ko not_active Ceased
- 1998-11-04 NZ NZ502874A patent/NZ502874A/en unknown
- 1998-11-04 BR BR9813539-2A patent/BR9813539A/pt not_active Application Discontinuation
- 1998-11-04 AU AU13060/99A patent/AU1306099A/en not_active Abandoned
- 1998-12-10 ZA ZA9811349A patent/ZA9811349B/xx unknown
-
2000
- 2000-02-25 IS IS5385A patent/IS5385A/is unknown
- 2000-06-09 NO NO20002965A patent/NO20002965L/no not_active Application Discontinuation
-
2003
- 2003-08-29 AU AU2003244047A patent/AU2003244047A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022116083A5 (https=) | ||
| FI3911648T3 (fi) | 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön | |
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| Muramatsu et al. | Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin | |
| JP2002508320A5 (https=) | ||
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| BG105559A (en) | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR | |
| RU2007126483A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| FI3666797T3 (fi) | Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9) | |
| JP2012107018A (ja) | Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートおよびＨＭＧ−ＣｏＡ還元酵素阻害剤を含む併用 | |
| MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
| JP2004521894A5 (https=) | ||
| CA2456732A1 (en) | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor | |
| JP2007512347A5 (https=) | ||
| Moghadasian et al. | Pharmacotherapy of hypercholesterolaemia: statins in clinical practice | |
| NZ603207A (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| ZA200102230B (en) | Method for preventing or delaying catheter-based revascularization. | |
| JP2003524582A5 (https=) | ||
| JP2007530528A5 (https=) | ||
| ATE550039T1 (de) | Mittel zur behandlung von glomerulären erkrankungen | |
| JP2002506818A5 (https=) | ||
| CA2529367A1 (en) | Preventing atrial fibrillation (af) with the use of statin drugs | |
| Kurata et al. | Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia | |
| PE20000348A1 (es) | Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina | |
| JPWO2001085155A1 (ja) | 動脈硬化抑制方法及び組成物 |